Trading Places—Switching Frataxin Function by a Single Amino Acid Substitution within the [Fe-S] Cluster Assembly Scaffold. Dean DR, Dos Santos PC (2015) PLoS Genet 11(5): e1005192. doi:10.1371/journal.pgen.1005192
Full text pdf
Thursday, May 21, 2015
Turning Saccharomyces cerevisiae into a Frataxin-Independent Organism
Turning Saccharomyces cerevisiae into a Frataxin-Independent Organism. Yoon H, Knight SAB, Pandey A, Pain J, Turkarslan S, Pain D, Andrew Dancis. (2015) PLoS Genet 11(5): e1005135. doi:10.1371/journal.pgen.1005135
Full text pdf
Full text pdf
Wednesday, May 20, 2015
Use of MAPK pathway inhibitors for the treatment of Friedreich Ataxia
Use of MAPK pathway inhibitors for the treatment of Friedreich Ataxia . University of Pennsylvania, posted on 05/19/2015
Brief Description: A novel treatment for rare disease Friedreich ataxia using p38 or MK2 kinase inhibitors
Brief Description: A novel treatment for rare disease Friedreich ataxia using p38 or MK2 kinase inhibitors
A First in Human Study of RT001 in Patients With Friedreich's Ataxia
A First in Human Study of RT001 in Patients With Friedreich's Ataxia.ClinicalTrials.gov Identifier: NCT02445794, Sponsor: Retrotope, Inc.
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Estimated Enrollment: 18
Study Start Date: July 2015
Estimated Study Completion Date: February 2016
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Estimated Enrollment: 18
Study Start Date: July 2015
Estimated Study Completion Date: February 2016
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
The Cardiomyopathy in Friedreich’s Ataxia – New Biomarker for Staging Cardiac Involvement
The Cardiomyopathy in Friedreich’s Ataxia – New Biomarker for Staging Cardiac Involvement. Frank Weidemann, Dan Liu, Kai Hu, Cristiane Florescu, Markus Niemann, Sebastian Herrmann, Bastian Kramer, Stephan Klebe, Kathrin Doppler, Nurcan Üçeyler, Christian Oliver Ritter, Georg Ertl, Stefan Störk, International Journal of Cardiology, Available online 15 May 2015, ISSN 0167-5273, http://dx.doi.org/10.1016/j.ijcard.2015.05.074.
FULL TEXT PDF
FULL TEXT PDF
A biomarker for determining mitochondrial damage in friedreich's ataxia
A biomarker for determining mitochondrial damage in friedreich's ataxia. Patent WO 2013130964, Pub. No.: WO/2013/130964, International Application No.: PCT/US2013/028609, Publication Date: 06.09.2013, International Filing Date: 01.03.2013
Applicants:INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION
Inventors: PAYNE, Ronald Mark; (US), WAGNER, Gregory R.; (US), BABBEY, Clifford M.; (US), PRIDE, P. Melanie; (US)
The compositions and methods include determining the acetylation status of mitochondrial proteins
Applicants:INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION
Inventors: PAYNE, Ronald Mark; (US), WAGNER, Gregory R.; (US), BABBEY, Clifford M.; (US), PRIDE, P. Melanie; (US)
The compositions and methods include determining the acetylation status of mitochondrial proteins
Thursday, May 14, 2015
Gene therapy possibilities for certain heart diseases
Gene therapy possibilities for certain heart diseases. Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University. By bioethicsnewsbot | May 13, 2015
Pill of super-protective 'heavy' fat may be key to eternal youth
Pill of super-protective 'heavy' fat may be key to eternal youth. 13 May 2015 by Jessica Hamzelou, New Scientist, Issue 3021
Mikhail Shchepinov, director of Retrotope, a biotech company based in Los Altos, California, wants eventually to slow down the ageing process. But he is starting with a related problem – treating the inherited movement disorder Friedreich's ataxia, with which ageing shares a mechanism.
The trial launching in June is a safety study. The team will be checking that the doses of heavy fat are well tolerated by 18 people with Friedreich's ataxia.
Mikhail Shchepinov, director of Retrotope, a biotech company based in Los Altos, California, wants eventually to slow down the ageing process. But he is starting with a related problem – treating the inherited movement disorder Friedreich's ataxia, with which ageing shares a mechanism.
The trial launching in June is a safety study. The team will be checking that the doses of heavy fat are well tolerated by 18 people with Friedreich's ataxia.
Metabolomics in Precision Medicine
Magazine Preview: Metabolomics in Precision Medicine. Ian Clift, Ph.D.; From May 15 Issue:Genetic Engineering & Biotechnology News
Dr. Blair studies Friedreich’s ataxia, a disease caused by a mutation in the gene frataxin or by a triplet GAA expansion in intron 1 of the gene
Dr. Blair studies Friedreich’s ataxia, a disease caused by a mutation in the gene frataxin or by a triplet GAA expansion in intron 1 of the gene
Wednesday, May 13, 2015
Ageing, neuroinflammation and neurodegeneration
Ageing, neuroinflammation and neurodegeneration. Roberta J Ward, David T. Dexter, Robert R. Crichton; Frontiers in Bioscience, Scholar, 7, 189-204, June 1, 2015
Subscribe to:
Posts (Atom)
